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Abbreviations:  BMI: body mass index, CF: cystic fibrosis, CFTR: Cystic fibrosis transmembrane conductance regulator, DEXA: dual energy X-ray absorptiometry; FEV1: forced expiratory volume in one second; FFM: fat free mass, FFMBIA: fat free mass by bioelectrical impedance analysis, FFMC: fat free mass corrected, FFMDEXA: fat free mass by dual energy X-ray absorptiometry , FFMI: fat free mass index, FMI: fat mass index, FRC: functional residual capacity,  FVC: forced vital capacity, LM: lean mass, LMT: lean mass trunk, LMTC: LMT corrected, LMTBIA: LMT by bioelectrical impedance analysis, LMUL: lean mass upper limbs, LMULBIA: lean mass upper limbs by bioelectrical impedance analysis, LMULC: LMUL corrected, LMULDEXA: lean mass upper limbs by dual energy X-ray absorptiometry, MEP: maximal expiratory pressure, MIP: maximal inspiratory pressure, MMEF25-75: maximal mid-expiratory flow between 25 and 75% of vital capacity, NIV: non-invasive ventilation, PFT: pulmonary function test,  RMFT: respiratory monitoring function test, Rrs5: respiratory system resistance at 5 Hz, Rrs20: respiratory system resistance at 20 Hz, RV: residual volume, TLC: total lung capacity.
ABSTRACT 
Background:  Nutrition is closely related to mortality and pulmonary and respiratory muscle function in cystic fibrosis (CF) patients. We initially validated results from a bioelectrical impedance device against dual energy x-ray absorptiometry (DEXA).  We then determined  whether fat free mass assessed by a portable impedance device rather than body mass index (BMI) better correlated with pulmonary function, respiratory muscle strength and exercise capacity in CF patients. 
Methods: Eighteen young people and adults (median age 19, range 12-39 years) with CF had dual energy X-ray absorptiometry and direct segmental multi-frequency impedance analysis. Body composition, pulmonary function, respiratory muscle function and exercise tolerance using the impedance device were measured in 29 young people with CF with median age 15 (range 12-19) years.
Main Findings: There was a significant correlation between impedance and absorptiometry results (r2=0.947). Fat free mass correlated with the forced vital capacity z-score (r=0.442, p=0.016), maximal inspiratory pressure (r=0.451, p=0.014) and exercise tolerance (r=0. 707, p<0.001). BMI z-scores did not significantly correlate with pulmonary or respiratory muscle function. Subjects with a fat free mass z-score of <2 had a lower forced expiratory volume in one second z-score (p=0.007), lower forced vital capacity z-score (p=0.001), higher residual volume z-score (p=0.042), lower maximal inspiratory pressure (p=0.039), more days of intravenous antibiotics per year (p=0.016) and a higher rate of chronic infections (p=0.006). 
Principal Conclusions: Fat-free mass measured by impedance correlated better with pulmonary and respiratory muscle function and exercise capacity than BMI. 






The current median predicted survival in UK patients with cystic fibrosis (CF) is 47 years [1] and respiratory failure remains the leading cause of mortality. The most rapid decline in pulmonary function is seen during adolescence with the forced expiratory volume in one second (FEV1). Nutrition is closely related to mortality in CF patients; those with a higher compared to a lower body weight have higher cumulative survival at five years [2].  Nutrition is also related to pulmonary and respiratory muscle function.  Adults with CF and a body mass index (BMI) below 20 had a markedly lower FEV1 than those with a BMI between 20 and 25 [3].   

BMI is used in the clinical setting to quantify the nutritional status of CF patients. Current guidelines recommend a BMI above the fiftieth percentile in children and adolescents to support optimal pulmonary function [4]. Measurements of the proportion of lean muscle, such as fat free mass and lean body mass, however, may better describe the nutritional status in CF. Engelen et al retrospectively analysed pulmonary function tests, BMI and body composition assessed by dual energy X-ray absorptiometry (DEXA). They identified a subgroup of CF patients who had a normal BMI, but low fat free mass and a lower FEV1 than those with normal fat free mass [5].  Peripheral muscle weakness has been described in children and adolescents with CF and knee extensor muscle strength has been shown to  moderately correlate with BMI [6]. Segmental lean body mass has not been assessed in CF children and young people in relation to pulmonary and respiratory muscle function tests.

DEXA scanning is used to estimate body composition, but involves ionizing radiation rendering it unsuitable for serial use. Alternatively, bioelectrical impedance analysis could be used. This method has been shown to give conflicting results when compared to DEXA in CF, potentially due to the affected electrical potentials from the underlying defect in chloride permeability and abnormal sodium transport [7, 8]. Validation of impedance analysis in relation to DEXA with a creation of a disease-specific equation has been suggested as a way of overcoming this [9]. An aim of this study was to validate a portable, segmental, multi-frequency impedance device to calculate body composition against DEXA results and to create CF specific equations.   
 
The main aim of this study was to determine whether fat free mass rather than BMI using a portable bioelectrical impedance analysis would better predict both pulmonary and respiratory muscle function. Furthermore, we examined whether pulmonary and respiratory function results correlated with exercise tolerance and assessed whether a specific distribution of lean body mass depletion related to pulmonary and respiratory muscle function or exercise tolerance.

MATERIALS AND METHODS  

Study design
Two studies were conducted between June 2016 and May 2017 at a tertiary CF centre at King’s College Hospital NHS Foundation Trust, London, UK. The first compared DEXA scan with impedance analysis performed on the same day in patients with CF aged 10 years and older. Patients were studied who were undergoing routine DEXA scans and gave informed written consent to also undergo impedance monitoring. The second study investigated clinically stable children and young people with CF who were aged between 12 and 19 years. Consecutive children and young people who fulfilled the inclusion criteria had none of the exclusion criteria and parents/patients gave informed written consent.  Age, gender and genotype were recorded. Genotype was classified into: ΔF508 homozygotes, ΔF508 heterozygotes, and other mutations. Information on the presence of chronic infection (three or more growths in the preceding 12 months) [10], CF-related diabetes, CF-related liver disease (abnormal liver enzymes and/or ultrasonography), pancreatic insufficiency, presence of percutaneous endoscopic gastrostomy tube and days of intravenous antibiotics administered in the past year was collected. 

Participants underwent body composition evaluation via bioelectrical impedance analysis, pulmonary, respiratory muscle and exercise tolerance tests. Exclusion criteria were pulmonary exacerbation in the past two-weeks and acute illness or hospitalisation. Ethical approval was granted by the London - Camberwell St Giles Research Ethics Committee for the first study and the East Midlands - Nottingham 2 Research Ethics Committee for the second study. Participants aged 16 years and older gave written consent whilst participants younger than 16 years gave written assent and consent was provided by their parents/guardians. 

Methods – Study one
Body composition was measured firstly with DEXA Lunar Prodigy (GE, Healthcare, Belgium) followed by bioelectrical impedance analysis with the Inbody S10 Body Composition Analyzer (Inbody Ltd, Cerritos, California, USA). Body composition was estimated by impedance using the four compartment model representing the body in terms of water, protein, fat and mineral components. Inbody S10 measures impedance separately in the four limbs and trunk. Body mass index (BMI), fat free mass, fat mass and segmental lean mass (LM)-upper limbs, LM-trunk, LM-lower limbs were recorded. Measurements were taken using the tetra-polar 8-Point Tactile Electrode system in the sitting position, following two-hours of fasting and micturition within 30 minutes prior to testing. 

Methods – Study two
Anthropometric measurements & body composition
Height, weight and body composition using Inbody S10 were measured and BMI-z scores and percentiles were calculated [11]. Fat free mass and fat mass were adjusted using the correction equation generated in the first study. 

Pulmonary function testing




Modified shuttle walk test
Patients walked/run between two cones, on a flat, enclosed corridor following externally paced instructions and standardised encouragement by the research team. Initial walking speed of 0.50m/s was increased by 0.17m/s every minute until the participant either completed all 15 levels, became too breathless to maintain the speed required, or failed to complete the shuttle within the allowed time. 

Habitual activity estimation scale 
Participants completed the Habitual Activity Estimation Scale (HAES) on the assessment day with the assistance of their parents and/or members of the research team as needed. They approximated the percentage of an average weekday and an average weekend day where they were inactive (lying down), somewhat inactive (sitting), somewhat active (walking) and active (activities that make you breathe hard and increase your heart rate). They recorded their waking, sleeping and meal times, allowing the research team to calculate the hours that they spend on each of these activity levels. The hours of being somewhat active and active were combined to calculate the time they spend being moderately-vigorously active during a weekday and a weekend day. 

Analysis
According to the European guidelines, a BMI percentile above the fiftieth is recommended to optimise pulmonary function [17].  A fat free mass index z-score less than -2 was used to define nutritional impairment by fat free mass [18]. Using paediatric body composition reference data, we compared the difference in pulmonary function tests, respiratory muscle function tests and exercise parameters in nutritionally impaired participants, by fat free mass index z-score and BMI percentile [19]. 
Respiratory muscle strength 
Maximal inspiratory and maximal expiratory pressures were assessed using a handheld, non-invasive manometer following lung function testing according to ATS/ERS guidelines (Micro RPM Respiratory Muscle Analyser, CareFusion, San Diego, California, USA) [20]. 

Exercise tolerance and activity
Exercise tolerance was assessed using the modified shuttle walk test.  Habitual activity was estimated using the habitual activity estimation scale.

Sample size 
A sample of 17 participants allowed detection of a correlation between fat free mass derived by DEXA and fat free mass derived by impedance of 0.7 with 90% power at the 5% level of statistical significance. A sample size of 29 patients allowed calculation of a correlation of 0.5 with 80% power at the 5% significance level between body composition, pulmonary function, respiratory muscle function and exercise test results [21, 22].  

Statistical analysis
Bland-Altman plots were produced to assess the agreement between the two methods. Relationships between pulmonary function, respiratory muscle function, body composition and exercise variables were examined using Spearman rho bivariate correlation analysis (r). Data on pulmonary function, respiratory muscle function, body composition and exercise were recorded as continuous variables. Data were tested for normality with the Kolmogorov Smirnoff test and were found to be non-normally distributed. Agreement between impedance analysis and DEXA results was evaluated with Bland-Altman analysis. We evaluated the corrected fat free mass as generated by our data as well as using the corrected fat free mass according to the equation generated by Charatsi et al [18]. Spearman rho non-parametric bivariate correlation analysis (r) was used to investigate the relationship between body composition measurements measured by impedance and DEXA. Multiple linear regression analysis generated a correction equation for impedance measurements. Multiple linear regression analysis was used to create CF-specific equations for body composition measured by bioelectrical impedance analysis (panel A, Figure 1) producing corrected-for-CF body composition measurements. The equation for corrected fat free mass (FFMC) is depicted below: 
FFMC = -2.844 – (0.184 x Weight) + (1.202 x FFMBIA)

Where FFMBIA is the fat free mass generated by bioelectrical impedance analysis. 





Body composition was measured in 18 young people and adults with CF with a median age (range) of 19 (12 – 39) years using impedance analysis and DEXA (Table 1).  There was a high correlation between impedance and DEXA results (R2 = 0.947, Figure 1).  CF-specific corrected equations for body composition measured by impedance were created (see Supplementary Table 1).  There was excellent agreement between impedance analysis and DEXA results (see Supplementary Figures 1 and 2).  




Categorical variables are expressed as number (n) and frequency (%).
Patients	18
Male sex	10 (55.6)
Age (years)	19 (12 - 39)
Height (cm)	163.4 (139.0 - 178.5)
Weight (kg)	56.6 (35.3 - 76.5)
FFMBIA (kg)	44.8 (25.2 - 65.1)
FFMDEXA (kg)	40.0 (23.5 - 61.7)
FMBIA (kg)	11.0 (2.9 - 24.7)
FMDEXA (kg)	14.9 (2.9 - 33.1)
LMULBIA(kg)	4.4 (1.9 - 7.0)
LMULDEXA (kg)	4.3 (1.9 - 8.0)
LMLLBIA(kg)	12.4 (5.6 - 20.2)
LMLLDEXA (kg)	11.4 (6.2 - 18.3)
LMTBIA(kg)	19.3 (10.7 - 27.5)
LMTDEXA(kg)	18.5 (10.8 - 28.5)

FFMBIA: fat free mass by bioelectrical impedance analysis, FFMDEXA: fat free mass by dual energy X-ray absorptiometry ,FMBIA: fat mass by bioelectrical impedance analysis ,FMDEXA: fat mass by dual energy X-ray absorptiometry, LMULBIA: lean mass upper limbs by bioelectrical impedance analysis, LMULDEXA: lean mass upper limbs by dual energy X-ray absorptiometry, LMLLBIA: lean mass lower limbs by bioelectrical impedance analysis, LMLLDEXA: lean mass lower limbs by dual energy X-ray absorptiometry , LMTBIA: lean mass trunk by bioelectrical impedance analysis, LMTDEXA: lean mass trunk by dual energy X-ray absorptiometry 


In the second study, 29 participants with a median age of 15 (range 12-19) years were studied (Table 2). 









CF related liver disease	9 (31.0)
CF related diabetes	5 (17.2)
Home O2/NIV	1 (3.5)
IV antibiotics (days/year)	10 (0 - 75)
BMI z-score		-0.09 (-2.73 - 1.19)
FFMI	13.07 (9.29 - 19.67)
FMI	6.64 (1.41 - 10.42)
FEV1 z-score	-1.87 (-5.70 - 0.82)
FVC z-score	-0.97 (-5.84 - 1.07)
FEV1/FVC z-score	-1.70 (-3.65 - 0.28)
MMEF25-75% z-score	-2.42 (-5.45 - 1.16)
FRC z-score	0.93 (-1.60 - 4.26)
RV z-score	1.83 (-1.14 - 4.98)
TLC z-score	1.08 (-0.51 - 4.20)
Rrs5 z-score	0.21 (-1.15 - 3.03)
Rrs20 z-score	0.79 (-1.07 - 3.60)
MEP % predicted	99.0 (64.7 - 138.9)
MIP % predicted	103.2 (45.8 - 146.2)
Shuttles	88 (32 - 150)
Moderate to vigorous activity (hrs/week)	11.3 (3.5 - 25.7)

CFTR: Cystic fibrosis transmembrane conductance regulator, NIV: non-invasive ventilation, BMI: body mass index,  FFMI: fat free mass index, FMI: fat mass index, FEV1: forced expiratory volume in 1 second,   FVC: forced vital capacity, MMEF25-75: maximal mid-expiratory flow between 25 and 75% of vital capacity, FRC: functional residual capacity,  RV: residual volume, TLC: total lung capacity, Rrs5: respiratory system resistance at 5 Hz, Rrs20: respiratory system resistance at 20 Hz, MEP: maximal expiratory pressure, MIP: maximal inspiratory pressure. 

The fat free mass index had a moderate positive correlation (r=0.40-0.59) with FVC z-score, maximal inspiratory pressure, maximal expiratory pressure and activity hours and a stronger positive correlation (r=0.60-0.79) with the number of shuttles achieved at the modified shuttle walk test. BMI z-score was not significantly correlated to any pulmonary function, respiratory muscle function or exercise indices (Table 3). Segmental lean body mass analysis showed that lean mass of upper limbs, lower limbs and trunk were significantly correlated to FVC z-score, maximal inspiratory and expiratory pressure and number of shuttles (Supplementary Table 2). None of the segmental body composition measurements, however, demonstrated a stronger correlation with pulmonary function results and exercise outcomes than the fat free mass index.

Table 3: Bivariate correlation of FFMI and BMI z-score with PF, RMF and indices of aerobic state. Spearman Rho correlation coefficients are presented.

	FFMI 	BMI z-score
FEV1 z-score	0.299 (p=0.115)	0.097 (p=0.616)
FVC z-score	0.442 (p=0.016)	0.178 (p=0.357)
MEP	0. 539 (p=0.003)	0.076 (p=0.696)
MIP	0.451 (p=0.014)	-0.086 (p=0.656)
Shuttles	0. 707 (p<0.001)	-0.061 (p=0.752)
Moderate to vigorous activity	0.471 (p=0.008)	0.153 (p=0.429)

FEV1: forced expiratory volume in 1 second, FVC: forced vital capacity, MEP: maximal expiratory pressure, MIP: maximal inspiratory pressure.

Subjects with a fat free mass index z-score of <2 had a significantly lower FEV1 z-score (p=0.007), lower FVC z-score (p=0.001), higher residual volume z-score (p=0.042), lower maximal inspiratory pressure (p=0.039), less shuttles run (p<0.001), more days of intravenous antibiotics per year (p=0.016) and a higher rate of chronic infections (p=0.006) (Table 4). In contrast, no significant difference was seen when comparing participants above and below the 50th BMI percentile (Table 4).  


Table 4: Comparison of PFTs, RMFTs and exercise outcomes according to nutrition












FEV1: forced expiratory volume in 1 second, FVC: forced vital capacity, RV: residual volume, MEP: maximal expiratory pressure, MIP: maximal inspiratory pressure, PFT: pulmonary function test,  RMFT: respiratory monitoring function test.








We have demonstrated that in children and young people with CF, fat-free mass correlated better than BMI with pulmonary function, respiratory muscle function and aerobic exercise. 
Our results contradict those of Pedreira et al who investigated 50 children and young adults with DEXA.  They found a weaker correlation between fat free mass and FEV1 compared to BMI (r=0.30 versus r=0.59 respectively) [23]. Those differences might be explained by population differences as 12 of 29 subjects in our cohort had a fat free mass z-score <2, while the Pedreira cohort had a mean fat free mass z-score of -0.87.  Our results are in agreement with Sheikh et al who analysed body composition in 208 pancreatic insufficient CF participants aged between 5 and 21 years using DEXA. They demonstrated that lean body mass had a stronger association with FEV1 than BMI [24]. Furthermore, in males with a BMI above the fiftieth percentile, low lean body mass was associated with worse pulmonary function. Those results support the hypothesis that the benefit of a normal/higher BMI to pulmonary function is derived from increased muscle mass [24]. Alvarez et al found greater adiposity to be independently associated with reduced lung function, especially when combined with low fat free mass, in a study of 32 adult CF subjects [25]. In our sample, fat free mass was negatively correlated to exercise tolerance, but showed no further significant associations. This may be due to the different age group studied. 

In a recent paper, Charatsi et al. reported similar results to our study using multifrequency impedance analysis in participants aged between 5 and 21 years [18]. The authors used impedance analysis which they validated against DEXA in 54 subjects and created a correction equation for fat free mass which they recommended for use with all impedance devices. We used their correction equation for fat free mass and the value generated did not agree with the DEXA measurements as accurately as the one generated by our correction equation highlighting the need to validate individual devices separately. Comparable to our results, they identified that a fifth of the included patients had fat free mass depletion, the great majority of whom had a normal BMI [18]. 

Our study has strengths and some limitations. We undertook a comprehensive assessment of children and young adults with CF which included an extensive assessment of nutritional status, pulmonary function, respiratory muscle function and aerobic status.  Having validated the impedance device against DEXA, the study can be replicated and applied in clinical practice using portable and affordable equipment which could be accessible to any CF centre. Assessment of body composition by DEXA and invasive respiratory muscle assessment by complex methodology such as diaphragmatic electromyography or the tension time index of the diaphragm [20] requires expensive, complex equipment and highly skilled staff to operate. In contrast, impedance analysis and maximal respiratory pressures measured by handheld manometers are relatively inexpensive and easy to perform in everyday clinical practice. A limitation of our study is that maximal respiratory pressures alone might fail to fully describe the pathophysiology of respiratory muscle impairment in CF. The measurement of maximal pressures alone cannot describe respiratory muscle function over time and the risk for impeding muscle fatigue [20].  It has, however, been shown that the main pathophysiological determinant of respiratory muscle impairment in CF is the loss of respiratory muscle strength [26] which can be accurately detected by measurements of maximal respiratory pressures.  

Evidence from our study and others [18] suggests that bioelectrical impedance analysis can be used in CF clinics to assess nutritional status. If increasing muscle mass proves to be beneficial for patients with normal BMI but low fat free mass, then targeted aerobic exercise could be introduced as an intervention and the fat free mass index thus potentially used as an index to monitor progress. In our study exercise tolerance had a positive correlation with pulmonary and respiratory muscle function (appendix A) and it has been shown that higher levels of aerobic activity are related to improved survival, pulmonary and respiratory muscle function in CF [27, 28].  
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	We validated a bioelectrical impedance device by dual energy x-ray absorptiometry.

	In CF patients there was a high correlation between impedance and DEXA.

	Free fat mass assessed by impedance correlated with pulmonary function results.

	Body mass index did not significantly correlate with pulmonary function results.
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